Vorinostat
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB02546 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 22 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary cutaneous B-cell lymphoma | KG + DL |
| 2 | Sezary syndrome | KG + DL |
| 3 | myeloid leukemia | KG + DL |
| 4 | lymph node cancer | KG + DL |
| 5 | seborrheic dermatitis | KG + DL |
| 6 | lymphosarcoma | KG + DL |
| 7 | relapsing-remitting multiple sclerosis | KG + DL |
| 8 | granulomatous slack skin disease | KG + DL |
| 9 | acute lymphoblastic leukemia (disease) | KG + DL |
| 10 | parapsoriasis | KG + DL |
| 11 | T-cell prolymphocytic leukemia | KG + DL |
| 12 | acute lichenoid pityriasis | KG + DL |
| 13 | primary organ-specific lymphoma | KG + DL |
| 14 | psoriasis | KG + DL |
| 15 | localized pagetoid reticulosis | KG + DL |
| 16 | folliculotropic mycosis fungoides | KG + DL |
| 17 | pityriasis lichenoides | KG + DL |
| 18 | upper aerodigestive tract neoplasm | KG + DL |
| 19 | T-cell leukemia | KG + DL |
| 20 | indolent primary cutaneous T-cell lymphoma | KG + DL |
| 21 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 22 | obsolete Hodgkin’s granuloma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.